0.97
+0.0166(+1.75%)
Currency In USD
| Previous Close | 0.95 |
| Open | 0.96 |
| Day High | 1.02 |
| Day Low | 0.93 |
| 52-Week High | 4.1 |
| 52-Week Low | 0.68 |
| Volume | 105,654 |
| Average Volume | 215,952 |
| Market Cap | 68.62M |
| PE | -2.1 |
| EPS | -0.46 |
| Moving Average 50 Days | 1.13 |
| Moving Average 200 Days | 1.75 |
| Change | 0.02 |
If you invested $1000 in Ovid Therapeutics Inc. (OVID) since IPO date, it would be worth $78.88 as of December 26, 2024 at a share price of $0.966. Whereas If you bought $1000 worth of Ovid Therapeutics Inc. (OVID) shares 5 years ago, it would be worth $196.4 as of December 26, 2024 at a share price of $0.966.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ovid Therapeutics to Present Multiple Posters Supporting Its Pipeline Programs Targeting Neuronal Hyperexcitability at the American Epilepsy Society 2024 Annual Meeting
GlobeNewswire Inc.
Dec 02, 2024 1:00 PM GMT
Two preclinical studies to be presented on OV329, a potential next-generation GABA aminotransferase inhibitor, highlighting its safety profile and lack of ocular accumulation relative to vigabatrin Findings to be presented on the effects of OV329 on
Ovid Therapeutics to Host Investor Event
GlobeNewswire Inc.
Oct 31, 2024 12:00 PM GMT
KCC2 Download Day on Wednesday, November 13, 2024NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditi
Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with Vigabatrin
GlobeNewswire Inc.
Sep 26, 2024 12:00 PM GMT
Study found OV329 cleared and remained undetectable in the retina, eye, and brain tissues of mice, unlike vigabatrin which has repeatedly shown to preferentially accumulate in mouse retinas, eyes, and other tissues OV329’s potency, mechanism of inhib